Medical/Pharmaceuticals
I-Mab Appoints U.S. Auditor, PricewaterhouseCoopers LLP (PwC)
Engagement is part of I-Mab's commitment to transition to a U.S.-based biotech PwC to serve as independent registered public accounting firm for FY 2024 ROCKVILLE, Md., Aug. 7, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) ("I-Mab", the "Company"), a U.S.-based, global biotech company, exclusively f...
2024-08-07 19:00
2014
Docquity Drives Demand for SIT Pharma's Duo Probiotics in Thailand, Achieving 31% Sales Growth in 6 months
* Docquity's Awareness to Advocacy (A2A) Program and strong local distribution network enabled SIT's duo probiotic sales to surpass the market growth rate of 15% * The technology platform boosted SIT's HCP education efforts, more than doubling its reach to 2,000 HCPs within six months and aim...
2024-08-07 10:05
3523
GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer
* Jemperli in combination with chemotherapy is the first immuno-oncology treatment approved in the frontline setting for this patient population in Singapore.[1,2] * Latest published local registry reported endometrial cancer as the fourth most common cancer and had the ninth highest cancer mo...
2024-08-07 09:00
2999
Senhwa Biosciences receives US FDA Study May Proceed letter for the Phase I/II study of Silmitasertib (CX-4945) in combination with chemotherapy in children and young adults with relapsed refractory solid tumors
TAIPEI and SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced receipt of a "Study May Proceed" letter from the U.S. Food and Drug A...
2024-08-07 08:49
3032
Datasea's Digital Technology Subsidiary Selected as Prospective Partner for Future Projects with Subsidiary of China Mobile
The Prospective Partnership with a Subsidiary of China Mobile, one of the World's Largest Mobile Operator, Underscores DTSS' Achievements in 5G-AI Communications BEIJING, Aug. 6, 2024 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), a digital technology company incorpora...
2024-08-06 21:30
2876
Lunit's AI for Tuberculosis Detection Tops in 12-Product Comparative Study
* Lancet Digital Health study highlights Lunit INSIGHT CXR as top performer in TB screening, showing promise for improving detection in high-burden settings SEOUL, South Korea, Aug. 6, 2024 /PRNewswire/ -- Lunit, a leading provider of AI-powered solutions for cancer diagnostics and therapeutics,...
2024-08-06 21:00
2619
PHYLEX VACCINE ON TRACK TO COMBAT DEADLY NIPAH VIRUS WITH POSITIVE RESULTS OF IMMUNOGENICITY STUDY
DEL MAR, Calif., Aug. 6, 2024 /PRNewswire/ -- Phylex Biosciences has achieved positive results with its new mRNA nanoparticle vaccine against the Nipah virus in an immunogenicity study conducted in collaboration with scientists of the U.S. Centers for Disease Control and Prevention (CDC) inAtlant...
2024-08-06 20:00
2515
Samsung Biologics joins the Pharmaceutical Supply Chain Initiative as Supplier Partner
* Samsung Biologics to embed PSCI principles into business practices for responsible value chain management * Supplier Partnership reaffirms company's commitment to decarbonize and build resilient supply chains INCHEON, South Korea, Aug. 6, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940....
2024-08-06 19:00
2544
Latest Updates of Viva Biotech's Portfolio Companies
HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the succ...
2024-08-06 18:47
3065
First patient enrollment in the U.S. - A milestone for the global multi-center phase Ⅲ clinical trial of telitacicept for myasthenia gravis
YANTAI, China, Aug. 6, 2024 /PRNewswire/ -- RemeGen Co. Ltd.
2024-08-06 17:00
3092
The Adecco Group: Q2 2024 Results
Further market share gains and disciplined cost management; G&A savings above-target ZURICH, Aug. 6, 2024 /PRNewswire/ -- * Revenues -2% yoy in challenging markets; Group relative revenue growth +375 bps and Adecco GBU +220 bps * Revenues by GBU, Adecco -2% yoy, Akkodis -2% yoy, LHH -7% yoy ...
2024-08-06 12:45
2185
First Patient Enrolled in the US Phase 2 Combination Therapy of Akeso's Ligufalimab with Azacitidine for Myelodysplastic Syndrome
HONG KONG, Aug. 6, 2024 /PRNewswire/ -- Akeso has announced the completion of the first patient enrollment in the US for the phase II clinical trial of its innovative CD47 monoclonal antibody, ligufalimab (AK117), in combination with azacitidine for patients with newly diagnosed higher-risk myelo...
2024-08-06 12:44
2423
OBiO Technology Congratulates on The First Clinical Gene Editing Therapy to Treat An Overseas Patient in China by CorrectSequence Therapeutics
SHANGHAI, Aug. 5, 2024 /PRNewswire/ -- Recently, CorrectSequence Therapeutics Co., Ltd. (Correctseq) announced a significant milestone in their base editing therapy CS-101 for transfusion-dependent β-thalassemia. Utilizing their pioneering transformer Base Editor (tBE), Correctseq has successfull...
2024-08-06 11:01
2640
Terumo Establishes Corporate Venture Capital "Terumo Ventures"
TOKYO, Aug. 6, 2024 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced that it has established "Terumo Ventures," a Corporate Venture Capital (CVC) organization responsible for leading the Group's venture investments, as a department within Terumo Americas Holding, Inc. Terumo Vent...
2024-08-06 09:00
3422
VISTA Eye Specialist Launches Corporate Program to Combat Rising Workplace Eye Issues
PETALING JAYA, Malaysia, Aug. 6, 2024 /PRNewswire/ -- VISTA Eye Specialist ("VISTA"), a leading provider of eye care services, today announced the launch of its Premier Corporate Partner Program. This initiative aims to combat the rising incidence of eye diseases, including dry eye caused by prol...
2024-08-06 08:00
2346
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia
* XPOVIO® is the first and only approved XPO1 inhibitor in Malaysia. * XPOVIO® has been approved for multiple indications in eight markets across the APAC region. Antengene has submitted new drug applications (NDAs) for XPOVIO ® in other ASEAN markets including Thailand and Indonesia with app...
2024-08-06 08:00
2847
Everest Medicines to Announce 2024 Interim Results on August 28, 2024
SHANGHAI, Aug. 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim result...
2024-08-06 07:30
3980
META Pharmaceuticals announces FDA Grants Rare Pediatric Disease Designation to META-001-PH for the Treatment of Primary Hyperoxaluria
HONG KONG, Aug. 5, 2024 /PRNewswire/ -- META Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to its investigational new drug META-001-PH for the treatment of primary hyperoxaluria (PH).Primary hyperoxaluria is a...
2024-08-05 21:52
2720
Shanton Reaches Full Enrollment in Phase 2b Refractory/Tophaceous Gout Study with SAP-001
SAP-001 is Shanton's lead investigational compound with Best-in-Class potential in uncontrolled gout PRINCETON, N.J., Aug. 5, 2024 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a groundbreaking treatment for refractory and tophaceous gout patients, today announced f...
2024-08-05 21:00
2399
Seegene Showcased its Multiplex Technology at ADLM 2024
- Exhibited multiplex PCR testing technologies that provide comprehensive results from a single test - Presented high-multiplex assays and automated testing systems - Introduced the SG OneSystem™ business, the company's global technology-sharing initiative SEOUL, South Korea, Aug. 5, 2024 /P...
2024-08-05 21:00
3306
Week's Top Stories
Most Reposted
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 310 media titles]
2026-02-26 09:30
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 308 media titles]
2026-02-26 19:57
SMU and Fudan Launch Region's First Tech-Focused DBA
[Picked up by 300 media titles]
2026-03-02 09:15Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale
[Picked up by 289 media titles]
2026-03-02 09:00
Klook's Spring Readiness Index shows how Asia's travelers are preparing for spring travel across Japan, South Korea, and Mainland China
[Picked up by 288 media titles]
2026-03-03 15:49
Most Read
COLUMBIA ASIA HOSPITAL BUKIT JALIL LAUNCHES NEW CATH LAB TO STRENGTHEN HEART CARE SERVICES
2026-03-02 14:24
8542
